Exenatide pulsatile release - Orbis Biosciences
Alternative Names: ORB-203Latest Information Update: 28 Jun 2023
At a glance
- Originator Orbis Biosciences
- Class Antihyperglycaemics; Obesity therapies; Peptides; Venoms
- Mechanism of Action Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Obesity; Type 2 diabetes mellitus
Most Recent Events
- 28 Jun 2023 No recent reports of development identified for preclinical development in Obesity in USA (Parenteral, Controlled release)
- 28 Jun 2023 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in USA (Parenteral, Controlled release)
- 04 May 2020 Orbis Biosciences has been acquired by Adare Pharmaceuticals